证券研究报告 建筑装饰 | 基础建设 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 30 日 证券分析师 王彬鹏 SAC：S1350524090001 wangbinpeng@huayuanstock.com 戴铭余 SAC：S1350524060003 daimingyu@huayuanstock.com 郦悦轩 SAC：S1350524080001 liyuexuan@huayuanstock.com 唐志玮 tangzhiwei@huayuanstock.com 林高凡 lingaofan@huayuanstock.com | 基本数据 | 29 | | | | 2025 | 年 | 04 | | 日 | 月 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | | 8.91 | | | | | 一 年 / 低 | | 最 | 高 | 内 | | | | 9.12/5.19 | | | 最 | | （元） | | | | | | | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The domestic production of "Hewei Zhengchang Wan" is imminent, and the clinical progress of the innovative drug for vitiligo is steady [5] - The company reported a revenue of 721 million yuan for 2024, a decrease of 5.23% year-on-year, and a net profit of 108 million yuan, down 32.45% year-on-year [7] - The company expects significant improvement in profitability following the domestic launch of gastrointestinal medications [7] Financial Performance Summary - Revenue projections for the company are as follows: 2023: 761 million yuan, 2024: 721 million yuan, 2025E: 902 million yuan, 2026E: 1,083 million yuan, 2027E: 1,296 million yuan [6] - The expected growth rates for revenue are -2.90% in 2023, -5.23% in 2024, 25.15% in 2025, 20.06% in 2026, and 19.60% in 2027 [6] - The projected net profit for 2025 is 176 million yuan, with a year-on-year growth of 62.37% [6] - The earnings per share (EPS) are forecasted to be 0.41 yuan in 2025, 0.56 yuan in 2026, and 0.71 yuan in 2027 [6] Business Segmentation - In 2024, the revenue breakdown is as follows: gastrointestinal medications: 206 million yuan (up 1.04% year-on-year), ophthalmic medications: 185 million yuan (up 0.13%), sexual health: 178 million yuan (down 20.87%), traditional Chinese medicine and external medications: 95 million yuan (down 10.03%) [7] - The company has made progress in its R&D pipeline, with the II phase clinical trial for CKBA ointment for vitiligo fully enrolled [7] - The company has received acceptance for the domestic listing application of "Hewei Zhengchang Wan" and is progressing with other innovative drugs [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company, Guoyao Yizhi, reported a revenue of 18.29 billion yuan in Q1 2025, a year-on-year decrease of 4.2%, and a net profit attributable to shareholders of 330 million yuan, down 15.6% year-on-year [5] - The distribution segment's revenue in Q1 2025 was 13.59 billion yuan, a decline of 2.6% year-on-year, while the retail segment generated 4.98 billion yuan, down 7.5% year-on-year, but turned profitable compared to previous quarters [8] - The company is expected to see improvements in profitability throughout 2025, with projected net profits of 1.33 billion yuan, 1.50 billion yuan, and 1.67 billion yuan for 2025, 2026, and 2027 respectively, indicating growth rates of 107.1%, 12.5%, and 11.7% [8] Financial Summary - As of April 29, 2025, the company's closing price was 24.53 yuan, with a total market capitalization of 13.65 billion yuan and a circulating market capitalization of 13.48 billion yuan [3] - The company's total assets are projected to grow from 50.08 billion yuan in 2025E to 56.78 billion yuan in 2027E, while total liabilities are expected to increase from 28.07 billion yuan to 31.76 billion yuan over the same period [9] - The company's return on equity (ROE) is forecasted to improve from 3.64% in 2024 to 7.91% in 2027 [7]

证券研究报告 医药生物 | 生物制品 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 30 日 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 李强 SAC：S1350524040001 liqiang01@huayuanstock.com 市场表现： | 基本数据 | | | 2025 | 年 | 04 | 月 | 29 | 日 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | 22.04 | | | | 一 年 内 高 / 低 | 最 | 最 | | | | | | | 30.48/19.46 | | （元） | | | | | | | | | | | 总市值（百万元） | | | | | | | 16,112.89 | | | | 流通市值（百万元） | | | | | | | 15,933.44 | | | | 总股本（百万股） | | | | | | | 731.07 | | | | 资产 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company has successfully expanded its product boundaries through its dual subsidiaries, with the KAYO brand gaining recognition in potential markets such as the Far East and South America [5][7] - In 2024, the company achieved a revenue of 527 million yuan, representing a year-on-year increase of 10.06%, and a net profit attributable to shareholders of 56.14 million yuan, up 9.43% year-on-year [6] - The company’s export revenue accounted for 90.72% of total revenue in 2024, with significant growth in the Far East market due to strategic positioning amidst geopolitical changes [6][7] Summary by Sections Financial Performance - In Q1 2025, the company reported a revenue of 178 million yuan, a year-on-year increase of 264.24%, and a net profit of 11.52 million yuan, up 161.79% year-on-year [6] - The company plans to distribute a cash dividend of 5.95 yuan per 10 shares, totaling 33.37 million yuan [6] Market Expansion - The company has entered over 50 countries and regions, including North America, Europe, South America, and Oceania, with KAYO becoming a leading brand for youth off-road motorcycles in several markets [6] - The company has a diversified distribution strategy to mitigate risks from tariffs and price fluctuations, enhancing its market presence [6][7] Strategic Developments - The establishment of Huari Dynamic Technology and the acquisition of Chongqing Junchi Motorcycle aim to fill market gaps and expand the product matrix, particularly in the new energy sector [6][7] - Collaborations with Zhejiang University for developing competitive off-road motorcycle models have shown substantial progress in key technology research [6] Profit Forecast and Valuation - The projected net profits for 2025-2027 are 72 million, 91 million, and 113 million yuan, respectively, with corresponding EPS of 1.28, 1.62, and 2.02 yuan per share [6][7] - The current price-to-earnings ratios for 2025, 2026, and 2027 are estimated at 26.5, 21.0, and 16.9, respectively [6][7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company has experienced improved water conditions in 2024, leading to record high performance in Q1 2025. The revenue for 2024 was CNY 24.882 billion, a year-on-year increase of 6.05%, while the net profit attributable to shareholders was CNY 8.297 billion, up 8.63% year-on-year. In Q1 2025, the company achieved revenue of CNY 5.385 billion, a year-on-year growth of 21.84%, and a net profit of CNY 1.508 billion, reflecting a 41.56% increase year-on-year [7][5]. Financial Performance Summary - The company’s projected net profits for 2025-2027 are CNY 8.848 billion, CNY 9.042 billion, and CNY 9.274 billion respectively, with corresponding PE ratios of 19.5, 19.1, and 18.6 times [5]. - The company’s 2024 dividend policy is set at CNY 0.2 per share, with a dividend payout ratio of 43.39%, resulting in a dividend yield of 2.2% based on the stock price as of April 28, 2025 [5]. - The company’s total revenue is expected to grow from CNY 24.882 billion in 2024 to CNY 28.287 billion in 2027, with a compound annual growth rate of approximately 3.31% [8]. Operational Highlights - The company’s total installed capacity reached 31,008.5 MW by the end of 2024, with hydropower accounting for 27,305.8 MW and renewable energy for 3,702.7 MW. The completion of the Toba power station in 2024 is expected to contribute additional generation capacity [7]. - The company’s hydropower generation in 2024 was 1,120 billion kWh, a year-on-year increase of 4.62%, with significant contributions from improved water conditions in the Lancang River basin [7]. Market Context - The report emphasizes the long-term investment value of hydropower as a stable asset class in a volatile market, highlighting the market's re-evaluation of low-covariance assets like hydropower due to their stable business models and predictable performance [7].

Investment Rating - The investment rating for the company is "Buy" (maintained) due to relatively stable performance and good cost control [4]. Core Views - The company is expected to maintain steady growth in its core business, particularly in the distribution of narcotic and psychotropic drugs, benefiting from the increasing concentration in the pharmaceutical distribution industry [6]. - The company's revenue for Q1 2025 was 12.71 billion yuan, a year-on-year increase of 4.9%, while the net profit attributable to the parent company was 460 million yuan, a slight decrease of 0.1% year-on-year [6]. - The report highlights that the company's gross margin and expense ratios have remained stable, with a gross margin of 7% in Q1 2025, down 0.1 percentage points year-on-year [6]. Financial Performance Summary - Revenue projections for the company are as follows: - 2023: 49.696 billion yuan - 2024: 50.597 billion yuan (1.81% growth) - 2025E: 54.668 billion yuan (8.04% growth) - 2026E: 58.472 billion yuan (6.96% growth) - 2027E: 62.448 billion yuan (6.80% growth) [5]. - Net profit attributable to the parent company is projected as follows: - 2023: 2.146 billion yuan - 2024: 2.000 billion yuan (-6.80% growth) - 2025E: 2.203 billion yuan (10.14% growth) - 2026E: 2.381 billion yuan (8.08% growth) - 2027E: 2.545 billion yuan (6.91% growth) [5]. - The company's earnings per share (EPS) is expected to be: - 2023: 2.84 yuan - 2024: 2.65 yuan - 2025E: 2.92 yuan - 2026E: 3.16 yuan - 2027E: 3.37 yuan [5]. Market Performance - The company's market capitalization is approximately 21.798 billion yuan, with a circulating market value of about 15.986 billion yuan [2]. - The stock price closed at 28.89 yuan, with a one-year high of 38.00 yuan and a low of 27.12 yuan [2].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to achieve steady growth in plasma collection, leading to stable long-term performance [5] - The company maintains a leading position in the domestic market with a projected plasma collection volume of approximately 2,781 tons in 2024, representing a year-on-year growth of 15.15% [7] - The introduction of new products, such as the fourth-generation chromatographic immunoglobulin, is anticipated to significantly enhance profit margins [7] Financial Summary - Revenue projections for the company are as follows: - 2023: 5,180 million RMB - 2024: 6,032 million RMB (growth of 16.44%) - 2025E: 6,716 million RMB (growth of 11.35%) - 2026E: 7,633 million RMB (growth of 13.65%) - 2027E: 8,627 million RMB (growth of 13.02%) [6] - Net profit forecasts are as follows: - 2023: 1,110 million RMB - 2024: 1,549 million RMB (growth of 39.58%) - 2025E: 1,626 million RMB (growth of 4.93%) - 2026E: 1,859 million RMB (growth of 14.37%) - 2027E: 2,124 million RMB (growth of 14.25%) [6] - The company’s earnings per share (EPS) are projected to be: - 2023: 0.56 RMB - 2024: 0.78 RMB - 2025E: 0.82 RMB - 2026E: 0.94 RMB - 2027E: 1.07 RMB [6] Market Performance - The closing price of the company's stock is 19.10 RMB, with a total market capitalization of approximately 37,767.79 million RMB [3]

Investment Highlights - The report highlights the recovery of revenue growth for Yuyue Medical, with a significant increase in overseas sales, achieving a revenue of 7.57 billion yuan in 2024, down 5.1% year-on-year, and a net profit of 1.81 billion yuan, down 24.6% year-on-year [3][8] - Guotai Group's performance shows resilience in its civil explosives business, with a non-net profit growth of 17.09% year-on-year in Q1 2025, despite a slight revenue decline of 1.26% [12][13] - China Merchants Highway reported a revenue of approximately 2.803 billion yuan in Q1 2025, down 7.24% year-on-year, but net profit improved by 2.74% due to cost control and increased investment income [16][17] - Shenzhen Gas's main business in urban gas sales showed growth, with a revenue of 28.348 billion yuan in 2024, down 8.34% year-on-year, but a net profit increase of 1.19% [21][22] - New Industry's overseas business continued to grow rapidly, with a revenue of 4.535 billion yuan in 2024, up 15.41% year-on-year, and a net profit of 1.828 billion yuan, up 10.57% [25][26] - Huali Group's revenue in Q1 2025 grew by 12% year-on-year, driven by new brand collaborations and strong sales of sports shoes [30][31] - Bohai Leasing, a leading aircraft leasing company, reported a significant increase in aircraft sales revenue, reaching 12.7 billion yuan in 2024, up 61.08% year-on-year, driven by a strong aircraft market [35][36] - Weimao Electronics, an industrial intelligent connection control solution manufacturer, achieved a revenue of 260 million yuan in 2024, up 13.69% year-on-year, with a focus on expanding into emerging fields [39][40] Company-Specific Summaries Yuyue Medical (002223.SZ) - The company experienced a revenue decline in 2024 due to high base effects from the previous year, but Q1 2025 showed a recovery with a 9.2% year-on-year increase in revenue [3][9] - The product mix has led to a slight decrease in gross margin, with a 50.1% gross margin in 2024, down 1.2 percentage points year-on-year [10] - The company maintains a strong financial position with 7.08 billion yuan in cash and no short-term or long-term loans [10] Guotai Group (603977.SH) - The civil explosives business showed growth, with a revenue of 327 million yuan in Q1 2025, up 1.4% year-on-year [13][14] - The company faced a decline in electronic detonator sales but saw an increase in explosive engineering revenue [14][15] - The gross margin for Q1 2025 was 32.72%, down 0.5 percentage points year-on-year, but the non-net profit remained stable [15] China Merchants Highway (001965.SZ) - The company is actively pursuing expansion projects, including the ongoing reconstruction of key highways [17][18] - The net profit forecast for 2025-2027 is expected to grow steadily, with projected profits of 5.74 billion yuan in 2025 [18] Shenzhen Gas (601139.SH) - The urban gas sales volume increased by 2.78% in 2024, with significant growth in the Greater Bay Area [22] - The company is expected to benefit from lower upstream gas prices and increased sales volume [22][24] New Industry (300832.SZ) - The company reported a strong performance in overseas markets, with a 27.67% increase in overseas revenue [27] - The gross margin for 2024 was 72.26%, with a focus on expanding the product lineup in the chemical luminescence sector [28] Huali Group (300979.SZ) - The company maintained a strong partnership with major brands, resulting in a 12.34% revenue increase in Q1 2025 [30][31] - The company is expanding production capacity to meet growing demand, with a workforce increase of 17% [31] Bohai Leasing (000415.SZ) - The company is positioned as a global leader in aircraft leasing, with a fleet size of 1,158 aircraft [36] - The net profit forecast for 2025-2027 is expected to grow significantly, with a projected profit of 1.913 billion yuan in 2025 [37] Weimao Electronics (833346.BJ) - The company is focusing on the automotive and industrial automation sectors, with a projected growth in the vehicle wiring harness market [40][41] - The company is expanding its production capabilities to meet increasing demand in emerging markets [41]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's main business shows steady growth, with emerging and overseas momentum accelerating [4] - The company achieved a revenue of 555.34 billion yuan in Q1 2025, a year-on-year increase of 1.10%, and a net profit attributable to shareholders of 15.01 billion yuan, up 0.61% year-on-year [5] - The company continues to optimize its business structure, with strategic emerging industries achieving a revenue of 45.3 billion yuan, a year-on-year increase of 34.2% [5] - New contracts signed in Q1 2025 totaled 1,203.7 billion yuan, a year-on-year increase of 8.4%, with overseas contracts increasing significantly by 178.5% [5] - The company maintains a strong cash flow management, with a net cash outflow of 95.85 billion yuan in Q1 2025, a decrease of 7.43 billion yuan year-on-year [5] Financial Performance Summary - Revenue forecast for 2025 is 2,243.13 billion yuan, with a year-on-year growth rate of 2.56% [4] - Net profit attributable to shareholders for 2025 is projected at 47.54 billion yuan, with a growth rate of 2.93% [4] - The company's earnings per share (EPS) for 2025 is estimated to be 1.15 yuan [4] - The price-to-earnings (P/E) ratio for 2025 is projected at 4.79 [4]